CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

September 4th, 2012

FDA Warns Against Using Revatio in Kids with Pulmonary Hypertension

Revatio (sildenafil) should not be prescribed to children and adolescents with pulmonary arterial hypertension, according to an FDA MedWatch alert.

The warning is based on the results of a trial published in Circulation that showed increased mortality at medium and high doses of Revatio, compared with low-dose treatment, among patients aged 1 to 17 years. Low-dose Revatio did not improve exercise capacity.

The FDA notes that Revatio has never been approved to treat pulmonary arterial hypertension in children.

Reprinted with permission from Physician’s First Watch

Categories: Pediatric Cardiology, Vascular


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.